KCM
RYTM icon

Kennedy Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Kennedy Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
193,215
+127,397
+194% +$11.5M 0.38% 69
2026
Q1 		$5.72M Buy
65,818
+25,931
+65% +$2.52M 0.12% 260
2025
Q4 		$4.27M Buy
39,887
+312
+0.8% +$33.1K 0.09% 324
2025
Q3 		$4M Sell
39,575
-17,642
-31% -$1.64M 0.09% 330
2025
Q2 		$3.62M Buy
57,217
+2,287
+4% +$140K 0.09% 344
2025
Q1 		$2.91M Buy
+54,930
New +$3.05M 0.07% 373
2024
Q3 		– Sell
-11,154
Closed -$458K – 727
2024
Q2 		$458K Buy
+11,154
New +$445K 0.01% 641

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kennedy Capital Management's RYTM Position: Q2 2026 in Review

Kennedy Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 194% in Q2 2026, buying an estimated $11.5M and bringing the position to 193,215 shares worth $21.5M. The position accounts for 0.38% of the portfolio, ranked #69.

Kennedy Capital Management first reported a position in RYTM in Q2 2024 and has held it in 7 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Kennedy Capital Management held 193,215 shares of Rhythm Pharmaceuticals worth $21.5M as of Q2 2026.
  • Kennedy Capital Management bought 127,397 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $11.5M.
  • Rhythm Pharmaceuticals made up 0.38% of Kennedy Capital Management's portfolio in Q2 2026, its #69 holding.
  • Kennedy Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.